Adalimumab therapy for refractory uveitis: Results of a multicentre, open-label, prospective trial

British Journal of Ophthalmology

Volumn 97, Issue 4, 2013, Pages 481-486

  Suhler, Eric B ^a,b,c   Lowder, Careen Y ^d   Goldstein, Debra A ^e   Giles, Tracy ^b   Lauer, Andreas K ^b   Kurz, Paul A ^b   Pasadhika, Sirichai ^b   Lee, Shelly T ^b   De Saint Sardos, Alexandre ^b   Butler, Nicholas J ^b   Tessler, Howard H ^e,f   Smith, Justine R ^b,c   Rosenbaum, James T ^b,c,g  

^a PORTLAND VA MEDICAL CENTER   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d LERNER RESEARCH INSTITUTE   (United States)

^e UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^f NORTHWESTERN UNIVERSITY   (United States)

^g DEVERS EYE INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN A; INFLIXIMAB; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; STEROID; TACROLIMUS; VOCLOSPORIN;

ADULT; AGED; ARTHRALGIA; ARTICLE; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; COMMON COLD; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; EYE INFLAMMATION; HUMAN; HYPOGLYCEMIC COMA; MULTICENTER STUDY; NAUSEA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT OUTCOME; TREATMENT RESPONSE; UVEITIS; VISUAL ACUITY;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL, HUMANIZED; DRUG RESISTANCE; FEMALE; FLUORESCEIN ANGIOGRAPHY; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; UVEITIS; VISUAL ACUITY; YOUNG ADULT;

EID: 84875221455     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjophthalmol-2012-302292     Document Type: Article

References (30)

1. Gritz DC, Wong IG. Incidence and prevalence of uveitis in Northern California; the Northern California Epidemiology of Uveitis Study. Ophthalmology 2004;111:491-500; discussion (Pubitemid 38293104)
2. Suhler EB, Lloyd MJ, Choi D, et al. Incidence and prevalence of uveitis in Veterans Affairs Medical Centers of the Pacific Northwest. Am J Ophthalmol 2008;146:890-6 e8.
3. Suttorp-Schulten MS, Rothova A. The possible impact of uveitis in blindness: a literature survey. Br J Ophthalmol 1996;80:844-8. (Pubitemid 26345317)
4. Nussenblatt RB. The natural history of uveitis. Int Ophthalmol 1990;14:303-8. (Pubitemid 20350862)
5. Nussenblatt RB, Palestine AG. Uveitis: fundamentals and clinical practice. Chicago: Yearbook Medical Publishers, 1989.
6. Dana MR, Merayo-Lloves J, Schaumberg DA, et al. Prognosticators for visual outcome in sarcoid uveitis. Ophthalmology 1996;103:1846-53. (Pubitemid 26403738)
7. Jabs DA, Rosenbaum JT, Foster CS, et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol 2000;130:492-513.
8. Pasadhika S, Kempen JH, Newcomb CW, et al. Azathioprine for ocular inflammatory diseases. Am J Ophthalmol 2009;148:500-9 e2.
9. Robertson M, Liversidge J, Forrester JV, et al. Neutralizing tumor necrosis factor-alpha activity suppresses activation of infiltrating macrophages in experimental autoimmune uveoretinitis. Invest Ophthalmol Vis Sci 2003;44:3034-41. (Pubitemid 36759770)
10. Santos Lacomba M, Marcos Martin C, Gallardo Galera JM, et al. Aqueous humor and serum tumor necrosis factor-alpha in clinical uveitis. Ophthalmic Res 2001;33:251-5. (Pubitemid 34701624)
11. Biester S, Deuter C, Michels H, et al. Adalimumab in the therapy of uveitis in childhood. Br J Ophthalmol 2007;91:319-24. PMCID: PMC1857691. (Pubitemid 46586527)
12. Tynjala P, Kotaniemi K, Lindahl P, et al. Adalimumab in juvenile idiopathic arthritis-associated chronic anterior uveitis. Rheumatology 2008;47:339-44. (Pubitemid 351267203)
13. Suhler EB, Smith JR, Wertheim MS, et al. A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes. Arch Ophthalmol 2005;123:903-12. (Pubitemid 41057986)
14. Suhler EB, Smith JR, Giles TR, et al. Infliximab therapy for refractory uveitis: 2-year results of a prospective trial. Arch Ophthalmol 2009;127:819-22.
15. Galor A, Feuer W, Kempen JH, et al. Adverse Effects of Smoking on Patients with Ocular Inflammation. Br J Ophthalmol 2010;94:848-53.
16. Smith JR, Levinson RD, Holland GN, et al. Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease. Arthritis Rheum 2001;45:252-7. (Pubitemid 32952905)
17. Winthrop KL, Chiller T. Preventing and treating biologic-associated opportunistic infections. Nat Rev Rheumatol 2009;5:405-10.
18. Raja SC, Jabs DA, Dunn JP, et al. Pars planitis: clinical features and class II HLA associations. Ophthalmology 1999;106:594-9. (Pubitemid 30191598)
19. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. Neurology 1999;53:457-65.
20. Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol 2005;140:509-16. (Pubitemid 41224845)
21. Vazquez-Cobian LB, Flynn T, Lehman TJ. Adalimumab therapy for childhood uveitis. J Pediatr 2006;149:572-5. (Pubitemid 44468085)
22. Diaz-Llopis M, Garcia-Delpech S, Salom D, et al. Adalimumab therapy for refractory uveitis: a pilot study. J Ocul Pharmacol Ther 2008;24:351-61. (Pubitemid 351733224)
23. Callejas-Rubio J, Sanchez-Cano D, Serrano J, et al. Adalimumab therapy for refractory uveitis: a pilot study. J Ocul Pharmacol Ther 2008;24:613-14.
24. Rudwaleit M, Rodevand E, Holck P, et al. Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study. Ann Rheum Dis 2009;68:696-701.
25. Braun J, Baraliakos X, Listing J, et al. Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum 2005;52:2447-51. (Pubitemid 41117431)
26. Wendling D, Paccou J, Berthelot JM, et al. New onset of uveitis during anti-tumor necrosis factor treatment for rheumatic diseases. Semin Arthritis Rheum 2011;41:503-10.
27. Gangaputra S, Newcomb CW, Liesegang TL, et al. Systemic immunosuppressive therapy for eye diseases Cohort Study. Methotrexate for ocular inflammatory diseases. Ophthalmology 2009;116:2188-98.
28. Daniel E, Thorne JE, Newcomb CW, et al. Mycophenolate mofetil for ocular inflammation. Am J Ophthalmol 2010;149:423-32.
29. Kacmaz RO, Kempen JH, Newcomb C, et al. Cyclosporine for ocular inflammatory diseases. Ophthalmology 2010;117:576-84.
30. Pujari SS, Kempen JH, Newcomb CW, et al. Cyclophosphamide for ocular inflammatory diseases. Ophthalmology 117:356-65.